Induction of Influenza (H5N8) Antibodies by Modified Vaccinia Virus Ankara H5N1 Vaccine

Induction of Influenza (H5N8) Antibodies by Modified Vaccinia Virus Ankara H5N1 Vaccine

Bibliographic Details
Main Authors:	Rory D. de Vries, Heidi L.M. De Gruyter, Theo M. Bestebroer, Mark Pronk, Ron A.M. Fouchier, Albert D.M.E. Osterhaus, Gerd Sutter, Joost H.C.M. Kreijtz, Guus F. Rimmelzwaan
Format:	Article
Language:	English
Published:	Centers for Disease Control and Prevention 2015-06-01
Series:	Emerging Infectious Diseases
Subjects:	vaccine avian influenza MVA clinical trial antibodies zoonoses
Online Access:	https://wwwnc.cdc.gov/eid/article/21/6/15-0021_article

Similar Items

Diseño y construcción de vectores de transferencia para la obtención de virus vaccinia Ankara modificado (MVA) recombinantes Design and construction of transfer vectors in order to obtain recombinant modified vaccinia virus Ankara (MVA)
by: M. F. Ferrer, et al.
Published: (2007-09-01)

Developing Universal Influenza Vaccines: Hitting the Nail, Not Just on the Head
by: Lidewij C. M. Wiersma, et al.
Published: (2015-03-01)

Modified Vaccinia Virus Ankara as a Viral Vector for Vaccine Candidates against Chikungunya Virus
by: Juan García-Arriaza, et al.
Published: (2021-08-01)

E3L and F1L Gene Functions Modulate the Protective Capacity of Modified Vaccinia Virus Ankara Immunization in Murine Model of Human Smallpox
by: Asisa Volz, et al.
Published: (2018-01-01)

Efficacy and Safety of a Modified Vaccinia Ankara-NP+M1 Vaccine Combined with QIV in People Aged 65 and Older: A Randomised Controlled Clinical Trial (INVICTUS)
by: Chris Butler, et al.
Published: (2021-08-01)

Assessment of Immunogenicity and Efficacy of a Zika Vaccine Using Modified Vaccinia Ankara Virus as Carriers
by: César López-Camacho, et al.
Published: (2019-11-01)

Vaccination with Combination DNA and Virus-Like Particles Enhances Humoral and Cellular Immune Responses upon Boost with Recombinant Modified Vaccinia Virus Ankara Expressing Human Immunodeficiency Virus Envelope Proteins
by: Sailaja Gangadhara, et al.
Published: (2017-12-01)

Modified Vaccinia Virus Ankara (MVA) as Production Platform for Vaccines against Influenza and Other Viral Respiratory Diseases
by: Arwen F. Altenburg, et al.
Published: (2014-07-01)

Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara
by: Volker Sandig, et al.
Published: (2013-11-01)

MVA-based H5N1 vaccine affords cross-clade protection in mice against influenza A/H5N1 viruses at low doses and after single immunization.
by: Joost H C M Kreijtz, et al.
Published: (2009-11-01)

A Genotype of Modified Vaccinia Ankara (MVA) that Facilitates Replication in Suspension Cultures in Chemically Defined Medium
by: Volker Sandig, et al.
Published: (2013-01-01)

Reassortment between Avian H5N1 and human influenza viruses is mainly restricted to the matrix and neuraminidase gene segments.
by: Eefje J A Schrauwen, et al.
Published: (2013-01-01)

Plasmablast, Memory B Cell, CD4+ T Cell, and Circulating Follicular Helper T Cell Responses to a Non-Replicating Modified Vaccinia Ankara Vaccine
by: Evan J. Anderson, et al.
Published: (2020-02-01)

Influenza Antigens NP and M2 Confer Cross Protection to BALB/c Mice against Lethal Challenge with H1N1, Pandemic H1N1 or H5N1 Influenza A Viruses
by: Nutan Mytle, et al.
Published: (2021-08-01)

Possible Increased Pathogenicity of Pandemic (H1N1) 2009 Influenza Virus upon Reassortment
by: Eefje J.A. Schrauwen, et al.
Published: (2011-02-01)

A Soluble Version of Nipah Virus Glycoprotein G Delivered by Vaccinia Virus MVA Activates Specific CD8 and CD4 T Cells in Mice
by: Georgia Kalodimou, et al.
Published: (2019-12-01)

A Single Dose of Modified Vaccinia Ankara Expressing Lassa Virus-like Particles Protects Mice from Lethal Intra-cerebral Virus Challenge
by: Maria S. Salvato, et al.
Published: (2019-08-01)

Deletion of A44L, A46R and C12L Vaccinia Virus Genes from the MVA Genome Improved the Vector Immunogenicity by Modifying the Innate Immune Response Generating Enhanced and Optimized Specific T-Cell Responses
by: María Pía Holgado, et al.
Published: (2016-05-01)

Vaccination against human influenza A/H3N2 virus prevents the induction of heterosubtypic immunity against lethal infection with avian influenza A/H5N1 virus.
by: Rogier Bodewes, et al.
Published: (2009-01-01)

Wild Ducks as Long-Distance Vectors of Highly Pathogenic Avian Influenza Virus (H5N1)
by: Juthatip Keawcharoen, et al.
Published: (2008-04-01)

Low Virulence and Lack of Airborne Transmission of the Dutch Highly Pathogenic Avian Influenza Virus H5N8 in Ferrets.
by: Mathilde Richard, et al.
Published: (2015-01-01)

CD8+ T Cells Responding to the Middle East Respiratory Syndrome Coronavirus Nucleocapsid Protein Delivered by Vaccinia Virus MVA in Mice
by: Svenja Veit, et al.
Published: (2018-12-01)

Mengukur Kinerja Keuangan dengan EVA dan MVA
by: Bayu Wijayantini, et al.
Published: (2018-06-01)

Modified Vaccinia Virus Ankara Preferentially Targets Antigen Presenting Cells In Vitro, Ex Vivo and In Vivo
by: Arwen F. Altenburg, et al.
Published: (2017-08-01)

Vectors based on modified vaccinia Ankara expressing influenza H5N1 hemagglutinin induce substantial cross-clade protective immunity.
by: Annett Hessel, et al.
Published: (2011-01-01)

Highly Pathogenic Avian Influenza Virus (H5N1) Infection in Red Foxes Fed Infected Bird Carcasses
by: Leslie A. Reperant, et al.
Published: (2008-12-01)

Avian Influenza H5N1 in Tigers and Leopards
by: Juthatip Keawcharoen, et al.
Published: (2004-12-01)

Progress toward a universal H5N1 vaccine: a recombinant modified vaccinia virus Ankara-expressing trivalent hemagglutinin vaccine.
by: Mookkan Prabakaran, et al.
Published: (2014-01-01)

Deletion of Vaccinia Virus A40R Gene Improves the Immunogenicity of the HIV-1 Vaccine Candidate MVA-B
by: Patricia Pérez, et al.
Published: (2020-02-01)

PENGARUH MARKET VALUE ADDED TERHADAP HARGA SAHAM PADA PERUSAHAAN MANUFAKTUR
by: Rita Indah Mustikowati
Published: (2011-02-01)

Uma análise da correlação entre o EVA® e o MVA® no contexto das empresas brasileiras de capital aberto Correlation between Economic Value Added and Market Value Added for publicly owned Brazilian companies
by: José Odálio dos Santos, et al.
Published: (2005-03-01)

A Clinical Study on Management of Incomplete Abortion by Manual Vacuum Aspiration (MVA)
by: Arifa Akter Jahan, et al.
Published: (2012-07-01)

Sahiplik Yapısının Değer Odaklı Performans Ölçütleri Üzerindeki Etkisi: BİST İmalat Sektörü Üzerine Bir Uygulama
by: Emre Horasan, et al.
Published: (2021-06-01)

H-NS Family Proteins Drastically Change Their Targets in Response to the Horizontal Transfer of the Catabolic Plasmid pCAR1
by: Taisuke Nakamura, et al.
Published: (2020-05-01)

Combating COVID-19: MVA Vector Vaccines Applied to the Respiratory Tract as Promising Approach Toward Protective Immunity in the Lung
by: Reinhold Förster, et al.
Published: (2020-08-01)

Tauopathy Analysis in P301S Mouse Model of Alzheimer Disease Immunized with DNA and MVA Poxvirus-Based Vaccines Expressing Human Full-Length 4R2N or 3RC Tau Proteins
by: Juan García-Arriaza, et al.
Published: (2020-03-01)

Vaccinia Virus LC16m8∆ as a Vaccine Vector for Clinical Applications
by: Minoru Kidokoro, et al.
Published: (2014-10-01)

A modified vaccinia Ankara vaccine vector expressing a mosaic H5 hemagglutinin reduces viral shedding in rhesus macaques.
by: Nicholas W Florek, et al.
Published: (2017-01-01)

Traumatic spinal cord injury in southern Saudi Arabia: Patterns, time to surgery and outcomes
by: Ibrahim Alnaami, et al.
Published: (2021-01-01)

Analisis Perbandingan Kinerja Keuangan Sebelum Dan Sesudah Merger Dengan Menggunakan Metode Economic Value Added (Eva) Dan Market Value Added (Mva) Pada Pt Unilever Indonesia Tbk
by: Rakhmi Ayu Zulvina, et al.
Published: (2010-04-01)